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Introduction
More than 25 years after the identification of HIV as rhe causative agent of AIDS, the disease continues to spread in some countries [1] . Current antiretrovirals (ARVs) have significantly prolonged the time to both AIDS development and death in those infecced with HIV [2], although ARV success has ultimately been limited by toxicity, drug-drug interactions and other factors that determine patient compliance and, consequently, the emergence of resistance. Thus, there is a continuous need for existing agents to be improved and for the development of new drugs and drug classes that are effective, safe, have a higher genetic barrier to resistance. penetrare viral reservoirs more effectively and have activity against resisrant viruses. Another challenge is to develop strategies that maximize the efficacy of currently available drugs for as long as possible; how to start, when to start, how to change and when to change ARV therapy (ART) are all crucial elements of this strategy. However, it should be noted that access to new drugs and strategies serves no purpose if the chain of new infections is not broken and if the low levels of prevention and education that are currently in place persist. Unfortunately, relative to the advances
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Purpose of review To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview oÍ the most recent advances in HIV vaccine development. Recent findings There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigatìon, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, inductionmaintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase lll tria!.
Summary
Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/ AIDS while we await the develooment of an effective vaccine. made in treatment, prevention strategies have lagged behind considerably. The creation of an HIV vaccine represents the greatest hope for globally controlling the pandemic and preventing further socio-economic damage, and this will be the most important concern of the scientific communitv during this century. Owing to numerous factors, including the current lack of an effective HIV vaccine. there has been recent enthusiasm regarding the potential use of effective ART to prevent transmission of HIV, although well-designed trials are needed to determine the efficacy and feasibility of this strategy t3l. ln this rer ier,r. \Àe summarize recent advances in ARV agents, in ARV therapeutic straregies and in HIV vaccine develooment. Rilpivirine demonstrated antiviral efficacy in patients naìve to therapy in phase II clinical studies [5',6 ] and, as a result, is currently being evaluated in treatmentnaïr'e patients in two ongoing 96-week, randomized, double-blind, phase III trials, known as ECHO and THRIVE. Prelirninary pooled 4S-u'eek data from the phase III trials (n : 1368) suggest that once-daily rilpivirine 25 mg provides virological suppression noninferior to that of efavirenz, when used in combination with nucleoside reverse transcriptase inhibitors (NRTIs), with most patients in both treatment groups achieving HIV-I RNA levels of <50copies/ml (84.3% vs 82.3Vo ; between-group difference 2.0% [95Vo Cl -2.0,6.01) l7'1. \loreover, rilpivirine appears to have a good tolerabilitv profile. The most common adverse reactions to occur rvith rilpivirine in various trials included nausea, vonriting, headache and dizziness. Although rilpivirine was associated u.ith a l0% incidence of rash and, a 30Vo incidence of neuropslrchiatric disorders, the incidence <lf these events was lower than with the comoarator.
Overview of new ARVs under investigation
Rilpivirine offers the convenience of once-daily oral dosing (2.5 mg), and long-acting parenteral formulations are also uncler investigation [8] . Oral rilpivirine should alwavs be taken with food, as it increases exposure to the drug by 45% l9l.However, drugs, such as rifampicin, that induce the cl,tochrome P450 (CYP) enzvme, CYP3A,l, can reduce rilpivirine exposure and should therefore not be co-administered with rilpivirine [10] . Use of drugs that increase gastrointestinal pH, such as proton pump inhibitors (e.g. omeprazole) and H2-receptor antagonists (e.g. famotidine), may also reduce rilpivirine exposure [11, 12] . Consequently, proton purn;r inhibitors should not be coadministered with rilpivirine [11]; H2-receptor antagonists can be used, provided thev are administered several hours before or after rilpivirine [12] .
'fhree mutations have been identified as being associated rvith decreased susceptibility to rilpivirine in 'uìÍro (K101P, Y1u1I and Y181V) and the resistance profile of rilpivirine appears to be more robust than those of first-generation NNRTIs [13] . T'hus, rilpivirine mav represent a viable future NNR'Ì'I treatment option for ART-naïve patients and, like the second-generation NNRTI etravirine, mav potentially have use in the treatment of HlV-infected patients with resiscance to other NNRTIs, althor-rgh its use in this setting has vet to be evaluated. Elvitegravir Elvitegravir (GS-9137) is an HIV integrase inhibitor that inhibits the integration of viral DNA into the host's chromosomal l)NA.
'fhe drug has demonstrated potent antiviral activity against viruses r,r'ith resiscance to NNRTIs, NRTIs and protease inhibitors (PIs).
The antiviral efficacy of elvitegravir has been assessed preclominantly in treatment-experienced ;latients. One randomized, dose-ranging, phase II studv (n : 278) compared the efficacy of once-clail-v elvitegravir 20, .50 or I 2.5 mg boosted with ritonavir u'ith that of a comparator ritonavir-boosted PI (PI/r), in combination rvith an active backgrouncl regimen, in treatment-experienced patients [14']. The elvitegravir arms \\'ere found to be noninferior (50mg/day) or statistically superior (12.5 mg/dav; p-0.021) to the PI/r arm u'ith regard to the tin-ìe-weighted average change from baseline in HIV RNA levels through week 2,1 of therapy (-1.4,+ and -1.66 r's -1.19 logtocopies/ml-; intent-to-treat ['fT] analysis).
However, the elvitegravir 20mgJda.v treatment arm \\'as prematurely terminated following a review rif the data at 8 weeks lr'hich found high rates of virological failure. Use of a PI/r (clarunavir/r or tipranavir/r) r'vas permitted after week 8 in the remaining elvitegravir arms. As a result, the 16-week timepoint u'as considered to be che latest timepoint least likely to be affected by anv potentiall-y confbunding effects of PI/r addition; however, the findings at 16 weeks corroboratecl those of the 2'l-u'eek analvsis.
In addition, two ongoing, randomized, double-blincl, phase III trials are currentlv comparing once-dail-v elvitegravir/r with twice-daily raltegravir, in combination with a background regimen (a PI/r plus a second agent), in treatment-experienced patients [15, 16] .
Elvitegravir is metabolized by CYP3A4 and pharmacological studies have sholvn that it can be boosted rvith 100mg of ritonavir administered once daily. In combination u,ith ritonavir, the oral bioavailabilitv of elvitegravir is increased and its systemic exposure is increased =Z0-fold. As an alternative to ritonavir, the non-ritonayir boosting agent cobicistat is being evaluatecl. Elvitegravir has been coformulated u'ith emtricitabine, tenofovir disoproxil fumarate (DF') and cobicistat in a single t:rblet for once-daily adrninistration.'fhis fixed-dose combination (the Quad pill) was recently compared with oncedaily fixed-dose efavirenz/tenofovir DF/emtricitabine (AtriplaiL'') in a randomized, double-blind, phase II trial in treatment-naïve patients (n -71) [17'] . N'lost patients in each treatment group achieved an HIV RNA level of <50copies/ml after 2,1 weeks of therapy (90% vs 83%; lT"I' analysis), with the Quad pill meeting criteria for noninferiority relative to AtriplaiBr.
Elvitegravir/r does not appear to require dosage adjustment when co-administered r,vith NR'l'Is or NNRTIs [10, 18] . Similarly, the elvicegravir dosage (150mg/day) does not require adjustment upon co-administration with darunavir/r, tipranavir/r or fosamprenavir/r [10, 18, 19] , although should be reduced to 85 mg/day in combination r.vith atazanavir/r or lopinavir/r 120,211. The pharmacokinetics of elvitegravir/r are unaitered when coadministered 'uvith the CCR.5 inhibitor maraviroc, although as exposure to maraviroc is increased, a reduced maraviroc dosage may be requircd l?21.
With regard to other drugs, the dosage of rifabutin should be reduced to 150m9 once daily or three times weekly r,vhen coadministered with elvitegrav:r'lr 1231. Dosage adjustments are not required when elvitegravir/r is taken rvith omeprazole, although elvitegravir/r and antacids should be administered at least Zhours apart owing to a reduction in elvitegravir exposrrre upon coadministration [24] .
Elvitegravir demonstrated a good tolerability profile in the phase II triai, with the most commonly reported adverse events being upper respiratory tract infection, diarrhoea, nausea ancl fatigue [14']. The integrase n'ìutations that developed most commonlv with elvitegravir in this trial included 8148R/H/K, Nl55H, E92Q and E13BK [25] . Notably, raltegravir has been shown to select for mutations at these incegrase amino acid positions in aioo and evidence for cross-resistance between elvitegravir and raltegravir has been observed [25] .
Owing to its activity against HIV strains with resistance to other ARVs ancl its efficacy in treatment-experienced patients to date, elvitegravir should be a welcome addition to current salvage therapy options, particularly as it can be administered once daily. However, given the potentiallv low chreshold for resistance associated with integrase inhibitors, monotherapy should be avoided t261.
Vicriviroc \,'icriviroc maleate (SCH 417690; hereafter referred to as vicriviroc) is a new CCR.5 co-receptor antagonist, a class of drugs thac bind specificallv to the CCR5 co-receptor of the host cell, preventing entry of the virus. 'I'he antiviral activit)r of vicriviroc is generally similar to that of maraviroc (the first approved drug in this class), which is indicated for use in treatment-experienced pacienrs.
Vicriviroc, as a component of combination ART, was shown to provide virological suppression for up to 48 weeks in treatment-experienced patients infected with CCR5-tropic HIV in randomized, double-blind, phase II trials, known as VICTOR-E1 (n:114) and ACTG 5211 (n -118) 127 -291, with an open-label extension of VICTOR-E1 indicacing sustained antivirai efficacy with vicriviroc for up to 96 weeks [30] . Consequently, the efficacy of the drug in CCR5-tropic HIVinfected treatment-experience d patients is currently being evaluated in two identically designed, randomized, double-blind, phase III trials (n:857 randomized), known as VIC-I'OR-E3 and VICTOR-E,+, in which patients are treated with vicriviroc 30 mg or placebo once daily, in combination with an optimized background regimen (OBR) consisting of at least two ARVs. Pooled data from these studies showed no difference betll'een che vicriviroc and placebo groups for the proportion of patients with an HIV RNA level of <50 copies/ml after ,18 u''eeks of therapy (61Vo vs 6l%) I3l'1. However, vicriviroc appeared to be effective in those who had two or fewer ARVs in their OBR (70% vs 55% of placebo recipients; p -0.02) in further analyses [31' ].
In addicion, the efficacy of vicriviroc 30 mg once daily is currently being compared with that of tenofovir DF/emtricitabine, each in combination with atazanavirfr, in treatment-naïve patients with CCR5-tropic HIV infection in a phase III study [32] . Ifeffective, such a nucleosidesparing first-line creatment regimen would enable other classes of agents to be withheld for subsequent iines of therapy. Of note, an earlier phase II trial in treatmentnaïve patients was terminated prematurely owing to ln increased rate of virological failure in those who received vicriviroc 25 or 50 mg once daily relative to those who received efavirenz, each in combination with a dual NRTI regimen [33] .
Adverse events, such as headache (15%) and diarrhoea (10%) have been reported with vicriviroc. However, there is no record of serious side effects in humans, in particular those involving the central nervous system (CNS), such as seizures, which have occurred in animal species at very high plasma concentrations of vicriviroc. Furthermore, vicriviroc does not appear to be associated with serious laboratory or electrocardiographic abnormalities. Although certain malignancies developed in some treatment-experienced patients who participated in the phase II ACTG trial involving vicriviroc, a causal relationship with che drug was not considered to be determinable [28] and no new malignancies occurred during the excended follow-up of the trial [29] .
Vicriviroc is metabolized primarily by CYP3A4, has a half-life of 28-33hours (enabling once-dailv administration) and can be adminiscered with or without food Like NRTIs, PIs (which combine potency with a high genetic barrier to resistance) have also been studiecl as monotherapy. Lopinavir/r has been the PI most extensively studied in this setting, with data available from six randomized controlled studies. One such studv is the N{ONARK trial (n:138), which compared lopinavir/r with the triple combination of lopinavir/r, zidovudine and lamivudine in AR'f-naïve patients wich CD4-cell counts of > 100 cells/p,l-and HIV RNA levels of <100,000copies/mL [.51 ]. There were no significant differences between the treatment groups in terms of virological suppression after 24 or 48 weeks of therapv in the ITT analysis. However, major PI mutations were detected in 3 of 21 patients with virological failure in the lopinavir/r alone arm and in none of those with virological failure in the triple-therapy arm.
In a recent systematic revieu, of all Pl-monotherapy studies published in peer-reviewed journals or presented at conferences up to 2008 1521, the overall efficacv ofPI/r monotherapy was found to be inferior to that of HAAR'I, although the efficacy was improved if patienrs were started on monotherapy after having virological suppression for at least 6 months. 'I'his strategy is called induction-maintenance and is based on the assumption that after a phase of maximal suppressive HAAR'f (induction), the same level of viral suppression could be maintained by fewer drugs (maintenance). -frials using NRTIs and/or a Íìrst-generation PI as mainrenance therapv have produced variable findings [53] [54] [55] [56] [57] [58] , but PI/r monotherapy maintenance has also been studied in the past few years. Advantages of this approach would be reduction of side effects (including avoidance of long-term NRTI toxicity) ancl fewer drug inreracrions and costs. One further benefit could be reduction of ARV resistance, as failure of PI/r regimens seldom selects for major PI resistance mutations.
Overview oÍ new ARV therapeutic strategies
Although eraclication of HIV remains an elusive prospect, ART is now able to maintain viral suppression in infectecl individuals, preserving their imrnune sysrems for prolonged perio<ìs of time. The current standard of care fbr the treatment of HIV in the developecl world is highly active ART (HAART), usually a combination of two NRTIs ancl an NNRTI or Pl l4l,1Zl. However, concerns still exisr regarcling the long-term toxicity associated with chronic drug exposure, the need for daily medication adherencc, the developmenc of HIV resistance, drugdrug interactions and the costs associated with treatment. Several drug-sparing strategies are being explored to minimize ARV requirements.'Ì'hese include intermirrenr therap_v, induction-maintenance regimens rnd class-sparing combinations [,13 ].
Intermittent therapy was first thought ro be a srraregy rhar could reduce drug exposure and toxicitv, and usuallv consists of predefined periods on and off therapv, or scheduled treatnìent interruptions guided bv CD4+ cell However, PI monotherapy simplification strategies remain associated rvith concerns regarding limited penetration of the clrug into viral resevoirs ancl the possibility of viral replication in the CNS or genital tract [6,+] . With the introduction of new classes of agents, such as integrase inhibitors ancl CCR5 co-receptor antagonists, clther maintenance combinations arc possible, and studies are already unclerway to explore these very well tolerated drugs as components of alternative regimens [65] . In addition, cornbining raltegravir, the first approved integrase inhibitor, with a PI (either lopinavir/r, atazanavir or darunavir/r) is cLlrrentl-v being explored as a potential class-sparing approach in treatment-naiïe patients in several ongoing studies [66-6tj] . Indeed, AR'l'will continue to be developecl, with the aim of re<lucing toxicity, improvrng convenicnce and enhancing the potency and durability of response, while preserving patient quality of life.
Update on HIV vaccination reseaÍch
As currently available treatments are not effective in cradicating HlV, vaccination represents the optimal solution to the global impact of this infection. The primary goal of an H IV vaccine is to prevent the establishrnent of a ;rersistent infection, with the ideal vaccine being ablc to block infection completelv and provide sterilizing immunity [69] . However, an alternative, perhaps more realistic, vaccination goal is to lower the steadv-state viral load achieved after primary HIV-1 infection (i.e. the viral set point Antigen-presenting cells, such as dendritic cells (DC), are instrumental in inducing an immune response against HIV, although their functional capacity declines during the infection [70] . DCs have been investigated as a potential therapeutic vaccine approach, with around 50% of patients who received DCs loaded with inactivated autologous HIV-1 achieving viral load suppression withour ART in one study [82] . However, in another trial, administration of HIV peptide-loaded DCs followed by HAAR'| interruption did not reduce viral set poinrs beyond those observed before the initiation of HAART 1821.
Glinical trials using Íirst-generation HIV-1 vaccines
There are currently more than 30 trials evaluating preventive HIV vaccine candidates. However, despite a number of promising phase I and II studies, the most advanced candidates have so far been unsuccessful. In initial studies, HIV vaccine candidates with the hope of Approaches for the development of an HIV vaccine Several types of vaccine are currently licensed for human use: live-attenuated viruses. whole inactivated viruses and viral protein subunits 169,711. Although these traditional technologies have been very successful in generating vaccines against various viruses, they have not yet yielded a successful HIV vaccine. In spite of the fact that good short-term protection against the development of infection has been seen wich live-attenuated virus vaccines in non-human primates, the risks associated with using such HIV vaccines in humans have been too high, owing to the potential for vaccines ro generare virulent variants or cause disease in those who are immunocompromised. Although animal models initially gave some hope for whole inactivated virus vaccines, the protective immunity was later found to be mediated bv antibodies against human cellular proteins presenr in the outer membrane of the immunizing virus that had been incorporated during its production in human cell lines. Both whole inactivated virus and viral protein subunit vaccines provide immune protection mainly via the elicitation ofantibodies, but such vaccines have so far been unsuccessful in eliciting protective antibodies against HIV 17 ll. However, data from nonhuman primates suggest that incorporating'I'oll-like receptor adjuvants into HIV protein subunit vaccination strategies may increase their utility [77] . In addition to using adjuvanced proteins and peptides in vaccination, other new vaccine concepts and strategies include gene-deliverv technologies (e.g. live recombinant viral vectors, or DNA vaccines) and the combined use of at least rwo antigen delivery modalities in heterologous prime/boost regimens [69, 71] .
The use of viral vectors to deliver HIV antigens to specific target cells is the main strategy currently being explored. A great variety of viruses, including adenoviruses, poxviruses, parvoviruses, alphaviruses, paramyxoviruses, rhabdoviruses and herpesviruses, have been used co construct live and infectious recombinant vectors (e.g. ALVAC), and bacterial vaccine vectors, such as Bacillus Calmette-Guérin, Salmonella <tr Lìsterìa mono.y-
Recent advances in antiretroviral eliciting humoral antibody responses were evaluated, including synthetic peptides and recombinant proteins [83] . In spite of being safe and well tolerated, the subunit vaccine based on monomeric recombinant gp120 failed to pÍotect against HIV-1 infeccion because the elicited antibodies could not neutralize primary HIV-1 isolaces, despite showing some nelltralizing activity againsc laboratorv strains ìn aìtro. Although early vaccine studies were unsuccessful, manv lessons were learned from them as well as from fundamental tesearch on the HIV trnv orotein.
Glinical trials using second-generation HIV-1 vaccines
Once the potential role of cell-mediated immune responses in controlling HIV infection was recognized, researchers broadened cheir scope to evaluare vaccines that incorporated the more conseÍved internal proteins of HIV as well as the envelope, and gave more attention to evaluating vaccines that induced both humoral and cellmediated responses.
A randomized, double-biind, placebo-controlled, phase-III trial, known as RV144, was designed to evaluate the efficacy of the ALVAC-HIV vaccine (a non-replicating rcc<,,mbinant crnarvpox virrrs vector containing genes from HIV) boosted with the protein vaccine AIDSVAX B/E (gp120) in preventing HIV-1 infection.'Ihe trial was conducted in Thailand in 16,402 HlV-negative individuals and the results were recently published [84" ]. In the modified ITT analvsis, the vaccine had an efficacy of 31.2% (p-0.04 vs placebo). Further analysis of the immune responses generated in vaccinees is needed, r'vith an attempt to identify a correlate of protection. Follow-up clinical trials would also be beneficial in orcler to fully understand the vaccine effect and the potential for further vaccine development.
ln addition, phase I clinical trials have evaluated a trivalent mixture of recombinant adenovirus serotype 5 vectors (rAd5) expressing the Gag, Pol and Nef of clade B HIV-I. f)ata from these studies suggeste<1 that, in general, the vaccine was well tolerated and immunogenic, although pre-existing neutralizing antibodies against the vaccine vector were seen ro partially suppress the response to the vaccine [69] . Subsequently, two "proof-of-concept" phase IIb efficacy studies, known as
Step [80] and Phambili [85] , were initiated to determine if this vaccine could prevent HIV-1 infection or reduce viral krads post-infection in adults at high risk of HIV-1 infection. However, the studies were discontinued in 2007 because of a failure of the STEP trial to meet its efficacy enclpoints [80] . Furthermore, the vaccrne u,as associated with a greater number of HIV-1 infections than placebo in volunteers who had pre-existing Ad5-specific neucraÌizing antibodv titers, seemingly suggesting that treatment and prevention in H|V-inÍected patients Mallez et al. 527 rAd5 vector vaccines may be associaced lvith a higher, rather than lower, risk of contracting HIV in these indi- 
Conclusion
The prognosis of patients infected with HIV has improved dramatically over the last 26 years owing ro the introduction of numerous effective anti-HIV drugs. However, limitations, such as toxicity ancl the development of resistance, have continuously clriven the search for alternative agents, and several 'next-generation' agents are currently in development. Given the considerable progress that has been made in the treatment of HIV to dace, there is hope that future research will yield effective novel therapies to further extencl the current drug arsenal. In contrast, generating an effectir-c pÍeven-tative or therapeutic vaccine against HIV has proven to be much more difficult. HIV vaccines that incorporate HI\,' proteins/epitopes representing a broad range of strains and that induce a strong cross-reacrive immune Íesponse are needed, and aithough this has not yet been achieved, the field of HIV vaccine research is progressing. However, as HIV vaccine development u'ill continue to be a challenge, efficacy trials will certainlv require the collaboration of product developers, governments, funclers and researchcrs in multiple countries. 14 Zolopa AR, Berger DS, Lampiris H, ef a/. Ac'tivity oÍ elvitegravir, a once-daily . integrase inhibitor, against resistant HIV Type 1: results oí a phase 2, randomized, controlled, dose-ranging clinical trial. J InÍect Dis 2010; 2O1:81 4-822. The present study indicales lhat once-daily elvitegravir/ritonavir, in combination wath active background therapy, can provide effective virological suppression in treatment-experienced patients with HIV-1 infection.
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